1 / 16

Paclitaxel-Eluting Balloon Catheter for Coronary Artery Diseases

Explore the use of a drug-eluting balloon catheter for the treatment of stenoses in small coronary arteries and restenoses after stent deployment.

johnnyweaver
Download Presentation

Paclitaxel-Eluting Balloon Catheter for Coronary Artery Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show unsatisfactory long-term results even after drug-eluting stent deployment Likely Solution Using a drug-eluting balloon catheter (B.Braun Melsungen AG, Germany)

  2. Paclitaxel-eluting stent (DES) vs. Paclitaxel-eluting balloon (DEB) DES Hwang, Circulation 2001; 104: 600-5 Paccocath Scheller, Heart 2007; 2007;93:539-41

  3. The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease PEPCAD I-SVD PEPCAD II-ISR Martin Unverdorben Clinical Research Institute, Center for Cardiovascular Diseases Rotenburg an der Fulda, Germany On behalf of the PEPCAD Investigators

  4. Primary Variable • 6-month late lumen loss Secondary Variables • Procedural success (≤30% stenosis) • 6-month binary restenosis rate • 6-month MACE • MACE at 1 and 3 years

  5. Outcome Comparison *Stone, G JAMA 2005;294:1215-23

  6. Summary PEPCAD I • The paclitaxel-eluting balloon catheter Sequent Please (B.Braun Melsungen AG) … • was safe and associated with a high procedural success rate in de-novo lesions • exhibited low late lumen loss after 6 months in SVD • patients treated w/o additional stenting demonstrated a restenosis rate of 5.5%

  7. PEPCAD IIRandomized Comparison to Taxusin ISR

  8. Primary Variable • 6-month late lumen loss Secondary Variables • Procedural success (≤30% stenosis) • 6-month binary restenosis rate • 6-month MACE • MACE at 1 and 3 years

  9. As-Treated Groups Enrolled 131 Subj. Conventional balloon 1 Subj. Violator from DES

  10. Outcome (N=126) 2 NSTEMI side branch occlusion 4 non-cardiac death 1 1 protocol violators excluded 3cardiac, not lesion related

  11. Event Free Survival (ITT/As Treated) p=0.07 ITT p=0.007 As Treated Months post PCI

  12. Summary PEPCAD II • The paclitaxel-eluting balloon catheter Sequent Please (B.Braun Melsungen AG) … • was safe and associated with a high procedural success rate in ISR • exhibited low late lumen loss after 6 months in ISR • was superior to the paclitaxel-eluting Taxus stent in ISR after 6 months • has not been associated with late thrombosis in 200 patient years in SVD and ISR

  13. Additional Handouts

  14. Abbreviations and Terms

  15. Abbreviations and Terms

  16. Contact Information Martin Unverdorben MD, PhD, Associate Professor of Medicine +1 804 651 3089 (EST)  sbu135@comcast.net

More Related